Glucocorticoids in rheumatoid arthritis: the silent companion in the therapeutic strategy

References

• Giacomelli R, Gorla R, Trotta F, et al. Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. Rheumatology (Oxford). 2015;54(5):792–797.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4(1):18001.
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Straub RH, Wehling M, et al. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 2004;50(11):3408–3417.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964–975.
   PubMed Web of Science ®Google Scholar
• Gaujoux-Viala C, Nam J, Ramiro S, et al. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):510–515.
   PubMed Web of Science ®Google Scholar
• Bakker MF, Jacobs JW, Welsing PM, et al. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2012;156(5):329–339.
   PubMed Web of Science ®Google Scholar
• Machold KP, Landewé R, Smolen JS, et al. The stop arthritis very early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. Ann Rheum Dis. 2010;69(3):495–502.
   PubMed Web of Science ®Google Scholar
• de Jong PH, Quax RA, Huisman M, et al. Response to glucocorticoids at 2 weeks predicts the effectiveness of DMARD induction therapy at 3 months: post hoc analyses from the tREACH study. Ann Rheum Dis. 2013;72(10):1659–1663.
   PubMed Web of Science ®Google Scholar
• **Spies CM, Bijlsma JW, Burmester GR, et al., Pharmacology of glucocorticoids in rheumatoid arthritis. Curr Opin Pharmacol. 2010;10(3): 302–307.
   PubMed Web of Science ®Google Scholar
• Encio IJ, Detera-Wadleigh SD. The genomic structure of the human glucocorticoid receptor. J Biol Chem. 1991;266(11):7182–7188.
   PubMed Web of Science ®Google Scholar
• Hollenberg SM, Weinberger C, Ong ES, et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature. 1985;318(6047):635–641.
   PubMed Web of Science ®Google Scholar
• Almawi WY, Melemedjian OK. Molecular mechanisms of glucocorticoid antiproliferative effects: antagonism of transcription factor activity by glucocorticoid receptor. J Leukoc Biol. 2002;71(1):9–15.
   PubMed Web of Science ®Google Scholar
• Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol. 2008;4(10):525–533.
   PubMedGoogle Scholar
• Adcock IM, Lane SJ. Corticosteroid-insensitive asthma: molecular mechanisms. J Endocrinol. 2003;178(3):347–355.
   PubMed Web of Science ®Google Scholar
• Yudt MR, Jewell CM, Bienstock RJ, et al. Molecular origins for the dominant negative function of human glucocorticoid receptor beta. Mol Cell Biol. 2003;23(12):4319–4330.
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Scheffold A. Rapid glucocorticoid effects on immune cells. Steroids. 2002;67(6):529–534.
   PubMed Web of Science ®Google Scholar
• Sanden S, Tripmacher R, Weltrich R, et al. Glucocorticoid dose dependent downregulation of glucocorticoid receptors in patients with rheumatic diseases. J Rheumatol. 2000;27(5):1265–1270.
   PubMed Web of Science ®Google Scholar
• Croxtall JD, Choudhury Q, Flower RJ. Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. Br J Pharmacol. 2000;130(2):289–298.
   PubMed Web of Science ®Google Scholar
• Bartholome B, Spies CM, Gaber T, et al. Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and up-regulated after in vitro stimulation and in patients with rheumatoid arthritis. Faseb J. 2004;18(1):70–80.
   PubMed Web of Science ®Google Scholar
• Löwenberg M, Stahn C, Hommes DW, et al. Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. Steroids. 2008;73(9–10):1025–1029.
   PubMed Web of Science ®Google Scholar
• Löwenberg M, Verhaar AP, Bilderbeek J, et al. Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN. EMBO Rep. 2006;7(10):1023–1029.
   PubMed Web of Science ®Google Scholar
• Lightman SL, Conway-Campbell BL. The crucial role of pulsatile activity of the HPA axis for continuous dynamic equilibration. Nat Rev Neurosci. 2010;11(10):710–718.
   PubMed Web of Science ®Google Scholar
• Cameron A, Henley D, Carrell R, et al. Temperature-responsive release of cortisol from its binding globulin: a protein thermocouple. J Clin Endocrinol Metab. 2010;95(10):4689–4695.
   PubMed Web of Science ®Google Scholar
• Klieber MA, Underhill C, Hammond GL, et al. Corticosteroid-binding globulin, a structural basis for steroid transport and proteinase-triggered release. J Biol Chem. 2007;282(40):29594–29603.
   PubMed Web of Science ®Google Scholar
• Nenke MA, Lewis JG, Rankin W, et al. Reduced corticosteroid-binding globulin cleavage in active rheumatoid arthritis. Clin Endocrinol (Oxf). 2016;85(3):369–377.
   PubMed Web of Science ®Google Scholar
• Perretti M, Ahluwalia A. The microcirculation and inflammation: site of action for glucocorticoids. Microcirculation. 2000;7(3):147–161.
   PubMed Web of Science ®Google Scholar
• McEwen BS, Biron CA, Brunson KW, et al. The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions. Brain Res Brain Res Rev. 1997;23(1–2):79–133.
   PubMedGoogle Scholar
• Thiele K, Buttgereit F, Huscher D. Current use of glucocorticoids in patients with rheumatoid arthritis in Germany. Arthritis Rheum. 2005;53(5):740–747.
   PubMed Web of Science ®Google Scholar
• Buttgereit F. Do the treatment with glucocorticoids and/or the disease itself drive the impairment in glucose metabolism in patients with rheumatoid arthritis? Ann Rheum Dis. 2011;70(11):1881–1883.
   PubMed Web of Science ®Google Scholar
• Criswell LA, Saag KG, Sems KM, et al. Moderate-term, low-dose corticosteroids for rheumatoid arthritis. Cochrane Database Syst Rev. 2000;2:CD001158.
   Google Scholar
• Gotzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal anti-inflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev. 2004;3:CD000189.
   PubMedGoogle Scholar
• Gorter SL, Bijlsma JW, Cutolo M, et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69(6):1010–1014.
   PubMed Web of Science ®Google Scholar
• Duru N, van der Goes MC, Jacobs JW, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013;72(12):1905–1913.
   PubMed Web of Science ®Google Scholar
• Landewe RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002;46(2):347–356.
   PubMed Web of Science ®Google Scholar
• Boers M, Verhoeven AC, van der Linden S. Combination therapy in early rheumatoid arthritis: the COBRA study. Ned Tijdschr Geneeskd. 1997;141(50):2428–2432.
   PubMedGoogle Scholar
• van Tuyl LH, Boers M, Lems WF, et al. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis. 2010;69(5):807–812.
   PubMed Web of Science ®Google Scholar
• Goekoop-Ruiterman YP, de Vries-bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52(11):3381–3390.
   PubMed Web of Science ®Google Scholar
• Klarenbeek NB, van der Kooij SM, Guler-Yuksel M, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis. 2011;70(2):315–319.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Cipriani P, Masedu F, et al. Increased cardiovascular events and subclinical atherosclerosis in rheumatoid arthritis patients: 1 year prospective single centre study. PLoS One. 2017;12(1):e0170108.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Margiotta DPE, Macaluso F, et al. Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis: results from a cross-sectional, multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. Medicine (Baltimore). 2017;96(42):e8180.
   PubMed Web of Science ®Google Scholar
• Svensson B, Boonen A, Albertsson K, et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum. 2005;52(11):3360–3370.
   PubMed Web of Science ®Google Scholar
• Caporali R, Scirè CA, Todoerti M, et al. The role of low-dose glucocorticoids for rheumatoid arthritis in the biologic era. Clin Exp Rheumatol. 2013;31(4 Suppl 78):S9–13.
   PubMed Web of Science ®Google Scholar
• Hafstrom I, Albertsson K, Boonen A, et al. Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study. Ann Rheum Dis. 2009;68(4):508–513.
   PubMed Web of Science ®Google Scholar
• Kirwan JR, Bijlsma JW, Boers M, et al. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev. 2007;1:CD006356.
   Google Scholar
• Capell HA, Madhok R, Hunter JA, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis. 2004;63:797–803.
   PubMed Web of Science ®Google Scholar
• Hansen M, Podenphant J, Florescu A, et al. A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. clinical benefits and skeletal side effects. Ann Rheum Dis. 1999;58(11):713–718.
   PubMed Web of Science ®Google Scholar
• Santiago T, Jacobs JW, Saag KG, et al. Balancing the benefits and risks of low-dose glucocorticoid in rheumatoid arthritis. Acta Reumatol Port. 2015;40(1):10–22.
   PubMed Web of Science ®Google Scholar
• *Louveau B, De Rycke Y, Lafourcade A, et al. Effect of cumulative exposure to corticosteroid and DMARD on radiographic progression in rheumatoid arthritis: results from the ESPOIR cohort. Rheumatology (Oxford). 2018;1(57):1563–1573.
   Google Scholar
• Caporali R, Todoerti M, Scirè CA, et al. Oral low-dose glucocorticoids should be included in any recommendation for the use of non-biologic and biologic disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis. Neuroimmunomodulation. 2015;22(1–2):104–111.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3–15.
   PubMed Web of Science ®Google Scholar
• Derendorf H, Ruebsamen K, Clarke L, et al. Pharmacokinetics of modified-release prednisone tablets in healthy subjects and patients with rheumatoid arthritis. J Clin Pharmacol. 2013;53(3):326–333.
   PubMed Web of Science ®Google Scholar
• Straub RH, Cutolo M. Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum. 2007;56(2):399–408.
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Doering G, Schaeffler A, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. 2008;371(9608):205–214.
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Mehta D, Kirwan J, et al. Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis. 2013;72(2):204–210.
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Doering G, Schaeffler A, et al. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis. 2010;69(7):1275–1280.
   PubMed Web of Science ®Google Scholar
• Clarke LL, Jessop DS, Hunt LP, et al. Alleviation of morning joint stiffness by low-dose prednisone in rheumatoid arthritis is associated with circadian changes in IL-6 and cortisol. Int J Clin Rheumatol. 2011;6(2):241–249.
   Google Scholar
• Neumann V, Hopkins R, Dixon J, et al. Combination therapy with pulsed methylprednisolone in rheumatoid arthritis. Ann Rheum Dis. 1985;44(11):747–751.
   PubMed Web of Science ®Google Scholar
• Radia M, Furst DE. Comparison of three pulse methylprednisolone regimens in the treatment of rheumatoid arthritis. J Rheumatol. 1988;15(2):242–246.
   PubMed Web of Science ®Google Scholar
• Smith MD, Ahern MJ, Roberts-Thomson PJ. Pulse steroid therapy in rheumatoid arthritis: can equivalent doses of oral prednisolone give similar clinical results to intravenous methylprednisolone? Ann Rheum Dis. 1988;47(1):28–33.
   PubMed Web of Science ®Google Scholar
• Ruscitti P, Ursini F, Cipriani P, et al. Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study. PLoS One. 2017 Jul 12;12(7):e0181203.
   PubMed Web of Science ®Google Scholar
• Cipriani P, Berardicurti O, Masedu F, et al. Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study. Clin Rheumatol. 2017;36(2):251–260.
   PubMed Web of Science ®Google Scholar
• Choy EH, Kingsley GH, Khoshaba B, et al. A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. Ann Rheum Dis. 2005;64(9):1288–1293.
   PubMed Web of Science ®Google Scholar
• Carubbi F, Zugaro L, Cipriani P, et al. Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare. Int J Immunopathol Pharmacol. 2016;29(2):252–266.
   PubMed Web of Science ®Google Scholar
• Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364(9430):263–269.
   PubMed Web of Science ®Google Scholar
• Hetland ML, Stengaard-Pedersen K, Junker P, et al. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis. 2008;67(6):815–822.
   PubMed Web of Science ®Google Scholar
• Thiele S, Ziegler N, Tsourdi E, et al. Selective glucocorticoid receptor modulation maintains bone mineral density in mice. J Bone Miner Res. 2012;27(11):2242–2250.
   PubMed Web of Science ®Google Scholar
• Buttgereit F, Spies CM, Bijlsma JW. Novel glucocorticoids: where are we now and where do we want to go? Clin Exp Rheumatol. 2015;33(4 Suppl 92):S29–33.
   PubMed Web of Science ®Google Scholar
• Conrado DJ, Krishnaswami S, Shoji S, et al. Predicting the probability of successful efficacy of a dissociated agonist of the glucocorticoid receptor from dose-response analysis. J Pharmacokinet Pharmacodyn. 2016;43(3):325–341.
   PubMed Web of Science ®Google Scholar
• Weatherley B, McFadyen L, Tammara B. Population pharmacokinetics of fosdagrocorat (PF-04171327), a dissociated glucocorticoid receptor agonist, in patients with rheumatoid arthritis. Clin Transl Sci. 2018;11(1):54–62.
   PubMed Web of Science ®Google Scholar
• Safy M, de Hair MJH, Jacobs JWG, et al. Efficacy and safety of selective glucocorticoid receptor modulators in comparison to glucocorticoids in arthritis, a systematic review. PLoS One. 2017;12(12):e0188810.
   PubMed Web of Science ®Google Scholar
• van den Hoven JM, Van Tomme SR, Metselaar JM, et al. Liposomal drug formulations in the treatment of rheumatoid arthritis. Mol Pharm. 2011;8(4):1002–1015.
   PubMed Web of Science ®Google Scholar
• Vanniasinghe AS, Bender V. Manolios The potential of liposomal drug delivery for the treatment of inflammatory arthritis. Semin Arthritis Rheum. 2009;39(3):182–196.
   PubMed Web of Science ®Google Scholar
• Metselaar JM, Wauben MH, Wagenaarhilbers JP, et al. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long circulating liposomes. Arthritis Rheum. 2003;48(7):2059–2066.
   PubMed Web of Science ®Google Scholar
• Metselaar JM, van den Berg WB, Holthuysen AE, et al. Liposomal targeting of glucocorticoids to synovial lining cells strongly increases therapeutic benefit in collagen type II arthritis. Ann Rheum Dis. 2004;63(4):348–353.
   PubMed Web of Science ®Google Scholar
• Barrera P, Mulder S, Smetsers AI, et al. Long-circulating liposomal prednisolone versus pulse intramuscular methylprednisolone in patients with active rheumatoid arthritis. Arthritis Rheum. 2008;(Suppl):S453.
   Google Scholar
• Ferber E, Munder PG, Fischer H. Effect of dipyridamole and prednisolone on the lysophospholipase of erythrocytes. Biochem Z. 1966;344(2):218–220.
   PubMedGoogle Scholar
• Zimmermann GR, Avery W, Finelli AL, et al. Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug. Arthritis Res Ther. 2009;11(1):R12.
   PubMed Web of Science ®Google Scholar
• Paul-Clark MJ, Mancini L, Del Soldato P, et al. Potent antiarthritic properties of a glucocorticoid derivative, NCX-1015, in an experimental model of arthritis. Proc Natl Acad Sci USA. 2002;99(3):1677–1682.
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R, Wilson M, Fleischmann R, et al. Comparison of tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis. Ann Intern Med. 2009;151(4):229–240.
   PubMed Web of Science ®Google Scholar
• Listing J, Kekow J, Manger B, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis. 2015;74(2):415–421.
   PubMed Web of Science ®Google Scholar
• Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66(12):1560–1567.
   PubMed Web of Science ®Google Scholar
• Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65(3):285–293.
   PubMed Web of Science ®Google Scholar
• García-Gómez C, Nolla JM, Valverde J, et al. High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy. Eur J Clin Invest. 2008;38(9):686–692.
   PubMed Web of Science ®Google Scholar
• Choy E, Ganeshalingam K, Semb AG, et al. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford). 2014;53(12):2143–2154.
   PubMed Web of Science ®Google Scholar
• Tataranni PA, Larson DE, Snitker S, et al. Effects of glucocorticoids on energy metabolism and food intake in humans. Am J Physiol. 1996;271(2 Pt 1):E317–25.
   PubMed Web of Science ®Google Scholar
• Hoogwerf B, Danese RD. Drug selection and the management of corticosteroid-related diabetes mellitus. Rheum Dis Clin North Am. 1999;25(3):489–505.
   PubMed Web of Science ®Google Scholar
• Gurwitz JH, Bohn RL, Glynn RJ, et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. Arch Intern Med. 1994;154(1):97–101.
   PubMedGoogle Scholar
• Black DM, Filak AT. Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection. J Fam Pract. 1989;28(4):462–463.
   PubMed Web of Science ®Google Scholar
• Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69(2):325–331.
   PubMed Web of Science ®Google Scholar
• Hoes JN, Jacobs JW, Buttgereit F, et al. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol. 2010;6(12):693–702.
   PubMed Web of Science ®Google Scholar
• Zampeli E, Protogerou A, Stamatelopoulos K, et al. Predictors of new atherosclerotic carotid plaque development in patients with rheumatoid arthritis: a longitudinal study. Arthritis Res Ther. 2012;14(2):R44.
   PubMed Web of Science ®Google Scholar
• Grøn KL, Ornbjerg LM, Hetland ML, et al. The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the quest-RA program. Clin Exp Rheumatol. 2014;32(6):869–877.
   PubMed Web of Science ®Google Scholar
• Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005;52(3):722–732.
   PubMed Web of Science ®Google Scholar
• Poon M, Gertz SD, Fallon JT, et al. Dexamethasone inhibits macrophage accumulation after balloon arterial injury in cholesterol fed rabbits. Atherosclerosis. 2011;155(2):371–380.
   Web of Science ®Google Scholar
• Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11(6):954–963.
   PubMedGoogle Scholar
• Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 2007;56(6):1754–1764.
   PubMed Web of Science ®Google Scholar
• Widdifield J, Bernatsky S, Paterson JM, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013;65(3):353–361.
   PubMed Web of Science ®Google Scholar
• Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996;71(1):5–13.
   PubMed Web of Science ®Google Scholar
• Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68(7):1119–1124.
   PubMed Web of Science ®Google Scholar
• Garcia Rodríguez LA, Hernández-Díaz S. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. Arthritis Res. 2001;3(2):98–101.
   PubMedGoogle Scholar
• Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006;81(10):1361–1367.
   PubMed Web of Science ®Google Scholar
• Webster JI, Tonelli L, Sternberg EM. Neuroendocrine regulation of immunity. Annu Rev Immunol. 2002;20(1):125–163.
   PubMed Web of Science ®Google Scholar
• Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely Ill patients. N Engl J Med. 2003;348(8):727–734.
   PubMed Web of Science ®Google Scholar
• Buehring B, Viswanathan R, Binkley N, et al. Glucocorticoid-induced osteoporosis: an update on effects and management. J Allergy Clin Immunol. 2013;132(5):1019–1030.
   PubMed Web of Science ®Google Scholar
• Bultink IE, Baden M, Lems WF. Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother. 2013;14(2):185–197.
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Laan RF, Barton IP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003;48(11):3224–3229.
   PubMed Web of Science ®Google Scholar
• Mont MA, Pivec R, Banerjee S, et al. High-dose corticosteroid use and risk of hip osteonecrosis: meta-analysis and systematic literature review. J Arthroplasty. 2015;30(9):1506–1512.e5. .
   PubMed Web of Science ®Google Scholar
• Pereira RM. Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone Spine. 2011;78(1):41–44.
   PubMed Web of Science ®Google Scholar
• MacAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med. 1986;104(5):648–651.
   PubMed Web of Science ®Google Scholar
• Janssen NM, Genta MS. The effects of immunosuppressive and antiinflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med. 2000;160(5):610–619.
   PubMedGoogle Scholar
• Roubille C, Rincheval N, Dougados M, et al. Combe. Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort. Ann Rheum Dis. 2017;76(11):1797–1802.
   PubMed Web of Science ®Google Scholar
• Guler-Yuksel M, Hoes J-S, Bultink I, et al. Glucocorticoids, inflammation and bone. Calcified Tissue Int. 2018;102(5):592–606.
   PubMed Web of Science ®Google Scholar
• *den Uyl D, van Raalte DH, Nurmohamed MT, et al., Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum. 2012;64(3): 639–646.
   PubMed Web of Science ®Google Scholar
• **Emery P, Burmester GR, Bykerk VP, et al., Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period. Ann Rheum Dis. 2015;74(1): 19–26.
   PubMed Web of Science ®Google Scholar
• Ramiro S, Sepriano A, Chatzidionysiou K, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1101–1136.
   PubMed Web of Science ®Google Scholar
• Morgan CL, Emery P, Porter D, et al. Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data. Rheumatology. 2014;53(1):186–194.
   PubMed Web of Science ®Google Scholar